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Psychedelic-Assisted Psychotherapy for Existential Suffering:
Facilitating Self-Transcendence at the End-of-Life
Kevin O. St. Arnaud

Concordia University of Edmonton
Edmonton, AB, Canada
Although existential suffering is amongst the most devastating forms of
distress experienced by many patients nearing the end-of-life, it is often
unsatisfactorily addressed due to a paucity of effective interventions. However,
both historic and recent studies of psychedelic-assisted psychotherapy have
reported marked alleviation of this suffering. As such, this article seeks to
advance the rationale for the use of psychedelic substances in the provision
of psychedelic-assisted psychotherapy for patients nearing the end-of-life. It
begins with an overview of the classic psychedelics and their application in
psychotherapy, highlighting recent studies. This is followed with a conceptual
overview of existential suffering at the end-of-life and the process of selftranscendence. These sections are then integrated in a theoretical rationale for
psychedelic-assisted mystical states as a means of facilitating the development
of self-transcendence and, through it, the remediation of existential suffering.
The paper concludes with a discussion of practical and philosophical
considerations germane to the safe and ethical application of psychedelics
in healthcare. In particular, developmental considerations for assessing both
therapist and patient applicability in utilizing this modality are proposed.
Keywords: psychedelics, existential suffering, end-of-life care,
self-transcendence, positive adult development

E

xistential concerns have received increased
attention over the past few years due to growing
awareness of their central relevance to patient
well-being (Boston, Bruce, & Schreiber, 2011; Le
May & Wilson, 2008). In fact, severe existential
suffering is amongst the most devastating forms of
distress experienced by many patients nearing the
end-of-life (Cassel & Field, 1997; Greisinger et al.,
1996). However, despite both its severity and key
importance to patients’ quality of life (McClain,
Rosenfeld, & Breitbart, 2003), existential suffering
is rarely adequately addressed due to a paucity of
effective interventions (Gasser, Kirchner, & Passie,
2015). To date, there are no well-established
pharmacotherapies or psychosocial interventions,
and those commonly used demonstrate limited
efficacy (see Boston et al., 2011). However,
recent and historic studies exploring the utility of

psychedelic-assisted psychotherapy have found
that this modality can markedly alleviate existential
suffering in those approaching death.
Consequently, this article seeks to advance
the rationale for the provision of psychedelic-assisted
psychotherapy amongst patients experiencing
existential distress at the end-of-life. To do so, it
begins with an overview of the classic psychedelics
to first provide the reader with a basic orientation
to their history of use, neuropsychological features,
and method of application in psychotherapy.
Next, a conceptual outline of existential suffering
at the end-of-life and its relationship with the
developmental process of self-transcendence is
provided (in accordance with Boston et al., 2011,
this article uses the terms existential suffering and
existential distress interchangeably). It is argued that
psychedelic-induced mystical states may function
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to alleviate existential suffering by catalyzing
self-transcendence, thus aiding the resolution
of life’s final developmental crisis. Finally, given
that psychedelic-assisted psychotherapy is being
revisited as a treatment modality for a wide range
of psychological disturbances (Emerson et al., 2014),
this article concludes by addressing some of the
practical and philosophical considerations germane
to this approach more broadly. In particular,
guidelines to ensure patient safety will be paramount
for this approach to be more widely accepted.
Considerations for screening patients and training
psychedelic therapists based upon the tenets of
adult developmental and transpersonal psychology
are proposed.
The Classic Psychedelics
The use of psychedelic compounds for
spiritual and healing purposes dates back thousands
of years (Merlin, 2003). Psychedelic plants were—
and continue to be—venerated as sacraments
fostering social cohesion, healing, and spirituality
(Ludwig, 1972). In contemporary society, the term
psychedelic—deriving from the Greek roots psyche
(mind or soul) and delos (visible or manifest)—is
usually interpreted as mind manifesting. The number
of drugs that hold psychedelic properties includes a
range of substances with varying pharmacological
profiles. However, the drugs typically known as
classic psychedelics, such as psilocybin, lysergic acid
diethylamide (LSD), and mescaline, share a chemical
structure similar to the neurotransmitter serotonin (5HT), and are distinguished by their action as potent
serotonin agonists (Halberstadt, 2015).
Carhart-Harris and Nutt (2017) advanced
a bipartite model of the serotonergic system to
distinguish the neuropsychological effects of the
classic psychedelics from other drugs that modulate
serotonin receptors. In this model, serotonin
functions through two, distinct pathways. The
first is thought to modulate passive coping (stress
moderation) via the 5-HT1A receptor. This pathway
is enhanced by conventional antidepressants, such
as selective serotonin reuptake inhibitors (SSRIs),
as the 5-HT1A receptor is their principal site of
action. In such a way, conventional antidepressants
may be conceptualized as assimilative aids, in
the Piagetian sense, meant to help stabilize an
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individual through periods of adversity. Conversely,
Carhart-Harris and Nutt (2017) have suggested
that the second pathway modulates active coping
(neuropsychological plasticity/change in response
to stress) via the 5-HT2A receptor. This pathway is
believed to be enhanced by the classic psychedelics,
as they exert their primary effects via the 5-HT2A
receptor (Halberstadt, 2015). Accordingly, the
classic psychedelics may be conceptualized as
accommodative aids meant to help an individual
adapt by changing in response to adversity.
Phenomenologically, the classic psychedelics, like other psychoactive drugs, function
to induce a temporary non-ordinary state of
consciousness (Tart, 1975). In other words, they
may be thought of as a chemical key or nonspecific
amplifier of experience (Leary, Metzner, & Alpert,
2007). The description offered by Jaffe (1990) is
particularly illustrative of their effects, “the feature
that distinguishes the psychedelic agents from other
classes of drug is their capacity reliably to induce
states of altered perception, thought, and feeling that
are not experienced otherwise except in dreams or
at times of religious exaltation” (pp. 563–564).
However, because psychedelic compounds
serve to induct the user into a non-ordinary state
of consciousness, the content—and outcome—of
the experience greatly depends on the set, setting,
and matrix of the user (Eisner, 1997; Leary et al.,
1963). Set includes such factors as the intention,
personality, intelligence, and emotional state of
the individual, while setting includes the physical,
social, and symbolic parameters under which the
drug is taken. Finally, matrix includes the broader
environmental context from which the individual
comes from, and will return to, following the drug
experience. It must be strongly emphasized that
these non-pharmacological variables are primary,
rather than secondary, to understanding both the
nature of the psychedelic experience itself, as well
its impact on a given user (see Hartogsohn, 2017).
Although knowing that someone has
taken a psychedelic tells you little about the
explicit content of the experience itself, these
drugs, nonetheless, often induce a certain array of
psychological changes. These include: alterations
in sensation, cognition, and the perception of time
St. Arnaud

and space, novel interpretations of stimuli, changes
in language perception, increased associative
thinking, facilitation of novel insights and emotional
release, greater suggestibility, enhanced access to
unconscious memories and archetypal imagery, and
weakening ego boundaries (Masters & Houston,
1966).
It has been proposed that because psychedelics cause profound changes in one’s experience
of self, they may modulate the neural systems
currently believed to be associated with selfreferential processing—the default-mode network
(DMN; Carhart-Harris et al., 2014). Research
suggests that the classic psychedelics impact the
DMN in a reversible, dose-dependent manner, and
these changes appear to correlate with experiences
of self-dissolution (e.g., Carhart-Harris et al., 2016;
Nour & Carhart-Harris, 2017).
The History of Psychedelic-Assisted Psychotherapy
Throughout the 1950s and into the
1960s, psychedelic drugs were widely available
to researchers and clinicians in Europe and North
America, and initial studies reported promising
findings (Grinspoon & Bakalar, 1979). However,
by the late 1950s concerns began to grow due
to lax research ethics, questionable scientific
methodology, and media sensationalization (see
Novak, 1997). By the mid-1960s recreational
psychedelic use burgeoned, eventually leading to
their association with the growing counterculture
movement and anti-war sentiment. Taken together,
these factors culminated in the implementation
of harsh legal restrictions, which greatly curtailed
further study (Dyck, 2008).
However, although routine clinical use
of these compounds remains largely prohibited,
there has been a gradual re-emergence of both
experimental and clinical research in recent years
as regulations have begun to loosen (Johnson et al.,
2008). This new phase of contemporary research,
which employs more stringent ethics and research
protocols, supports the notion that these compounds
hold remarkable potential when carefully utilized.
Recent studies have reported promising findings of
their usefulness in palliative care (e.g., Griffiths et
al., 2016), addictions (e.g., Bogenschutz & Johnson,
2016), pain medicine (e.g., Frood, 2006), psychiatry

(e.g., Johnson & Griffiths, 2017), and criminology
(e.g., Hendricks et al., 2014).
Psychedelic-Assisted Psychotherapy
In contrast to most psychopharmaceuticals
the primary therapeutic utility of the psychedelic
drugs is not presumed to be a direct outcome of
their pharmacological action (Grinspoon & Bakalar,
1979; Richards, 2009). Rather, they modulate
neurological functioning to produce changes in
conscious awareness that—with the proper set,
setting, and guidance—can be highly conducive
to self-reflection, emotional catharsis, insight into
one’s existential situation, and transformative
mystical states (Sessa, 2017). In comparison to
pharmacotherapy, then, wherein drugs are often
meant to be taken repeatedly and continuously over
extended periods, psychedelics are typically used
sparingly to augment psychotherapy.
Historically, two major approaches to the
use of psychedelics were developed, psycholytic
and psychedelic psychotherapy (Grinspoon &
Bakalar, 1979). Psycholytic psychotherapy is usually
conceptualized from a psychodynamic perspective,
and utilizes smaller doses to augment the enhanced,
though gradual, release of unconscious material
over the course of numerous therapy sessions. In
comparison, psychedelic psychotherapy is usually
brief and aimed to induce a transformative mystical
experience in one, or a few, high dose therapy
sessions. A third approach, which is a combination
of the aforementioned methods, came to be
known as psychedelytic psychotherapy (Passie,
2007). Recent, contemporary clinical trials often
utilize either an analytic/psycholytic approach
or a humanistic/client-centered approach in the
application of these substances (see Phelps, 2017).
Although a variety of psychedelic-assisted
psychotherapy approaches and protocols have now
been developed, they typically involve three phases
of treatment: preparation for the psychedelic-assisted
session, the psychedelic session itself, and follow-up
integration sessions (Mithoefer, 2015; Passie, 2007).
A brief overview of some of the general, overarching
principles designed to ensure patient safety and
maximize beneficial outcomes is as follows (see also
Griffiths et al., 2016; Grob et al., 2011; Mithoefer,
2015; Pahnke, 1969; Richards et al., 1977).
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Typically, before the drug is administered,
the patient meets with two therapists over the
course of several sessions to establish rapport
and trust to prepare for the psychedelic session or
sessions (Mithoefer, 2015). Following this phase, the
individual is administered the drug in a pleasant
and welcoming environment with both therapists
present. Patients may be encouraged to lie down,
wear an eyeshade, use headphones to listen to
instrumental music, and focus their attention on their
arising inner experience. However, the patient may
decline to use the eyeshades and/or headphones at
any time. Tremendous care is placed on creating
a therapeutic set and setting, as these factors are
critical in shaping the experience and its outcomes
(Mithoefer, 2015).
The therapists are present throughout the
session to ensure safety; however, they typically
act supportively and non-directively, encouraging
participants to be trusting and fully open to their
experience (Phelps, 2017). As such, therapists adopt
a stance as empathic listeners, guides, facilitators of
emotional catharsis, and supporters of the patient’s
own inner healing agency. At times the therapists
may intervene by carefully inviting, rather than
directing, the patient back to his or her internal
experience (Mithoefer, 2015). Therapists follow,
rather than guide, the patient.
Integration sessions following the drug
session are considered essential for the psychedelic
experience to be most therapeutically impactful.
During non-drug follow-up sessions, the therapists
address any problems or concerns that may have
arisen following the drug-assisted sessions, and
help the patient to ground and conceptualize any
insights, such that they can be integrated into daily
functioning (Mithoefer, 2015).
Masters and Houston (1966) and Grof (1980)
both proposed that a given psychedelic experience
may be conceptualized as reaching four major
depths. The first, or sensory-aesthetic stratum,
involves changes in perception of sensory stimuli.
Normally unnoticed aspects of the environment
capture attention, and people and objects take
on a wondrous, fascinating quality. The second,
or psychodynamic stratum, involves revisiting
unresolved intra- and interpersonal conflicts,
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repressed memories, and emotional catharsis.
Deeper yet is the archetypal stratum, which involves
a sense of being a participant in the symbolic or
mythological drama of one’s life. Finally, at the
transpersonal or mystical stratum, one may have a
mystical experience, which entails self-dissolution
and a feeling of unity with something sensed to be
eternal, infinite, or sacred. Each of these experiential
depths may have clinical importance; however, the
mystical form may be especially therapeutic for
those nearing the end-of-life (Richards, 2016).
Adverse Effects and Contraindications
Substantial pharmacological, experimental,
and public health research has established that the
classic psychedelics are amongst the safest known
psychoactive substances, as they exhibit remarkably
low toxicity and are widely regarded to be nonaddictive (see Canal & Murnane, 2017; Gable,
2004; Passie et al., 2002, 2008). However, the
classic psychedelics can moderately increase pulse
rate and blood pressure; thus, use by individuals
with cardiovascular disease may be contraindicated
(see Johnson et al., 2008). In addition, medications
and over-the-counter products which modulate
serotonin (e.g., tricyclic antidepressants, SSRIs, St.
John’s Wort), as well as lithium and haloperidol,
have been shown to potentiate psychedelic effects,
rendering their concomitant use a potential safety
concern (Johnson et al., 2008).
Nonetheless, since the early 1990s
approximately 2000 doses of psilocybin (ranging
from low to high doses) have been safely administered
in the United States and Europe in controlled
settings, with no reports of any serious adverse
effects (Studerus et al., 2011). Any potential for harm
or abuse is heavily constrained by the supervised
nature of their administration, which is limited to
one or a few occasions, eliminating concerns about
abuse and/or adverse effects resulting from chronic
use (Shelton & Hendricks, 2016).
However, despite the limited nature of
adverse effects—particularly when used in a
therapeutic setting—confrontation with intensified
thoughts and emotions that often arise with the use
of these compounds may be upsetting for patients
(Gasser et al., 2015). Even in highly controlled
settings, high-dose psychedelics can produce very
St. Arnaud

strong psychological effects, including pronounced
feelings of anxiety, fear, paranoia, confusion, and
psychotic-like reactions (Griffiths et al., 2006;
Johnson et al., 2008; Strassman, 1984). Studerus et al.
(2011) further noted that an extremely small minority
of research participants who received psilocybin
in a therapeutic context experienced transient
anxiety and depression in the weeks following
administration. However, these adverse effects were
resolved within a month. Ultimately, very limited
harm has been reported in the contemporary era of
psychedelic research; when dosage, set, and setting
are carefully controlled, patients can typically
manage any challenging thoughts, emotions, or
memories that may arise. Importantly, research
suggests that even many elderly and ill patients
can safely manage the strong emotions evoked by
psychedelic compounds (see Richards, 2016).
Importantly, distressing psychedelic experiences are typically transient and have not been
shown to be causative of more enduring psychological
disturbances. For example, an epidemiological
study by Johansen (2013) found that psychedelic use
was not associated with psychosis or hallucinogen
persisting perceptual disorder (flashbacks). Similarly,
Krebs and Johansen (2013), using data from 2001 to
2004 from the National Survey on Drug Use and
Health, found that psychedelic use was associated
with a decreased likelihood of psychiatric symptoms.
However, although psychedelics do not appear
to evoke spontaneous mental illness or psychoses
in otherwise healthy individuals, it has been
proposed that they may precipitate these problems
in predisposed individuals (Nichols, 2016; Vardy
& Kay, 1983). Accordingly, the use of psychedelics
with those who have a psychotic disorder or are at
risk of developing one is typically considered one of
their major contraindications (Cohen, 1985; Johnson
et al., 2008).
Psychedelic-Assisted Psychotherapy
at the End of Life
Beginning in the 1960s, it was found that
psychedelic-assisted psychotherapy could help
improve mood, quality of life, and interpersonal
openness, and reduce depression, anxiety, and
fear of death in patients with life-limiting illnesses
(e.g., Grof et al., 1973; Kast, 1966; Richards et al.,

1977). Through the use of psychedelics, patients’
thoughts and feelings surrounding death could
be more fully experienced and explored, thus
helping patients achieve a sense of meaning and
acceptance (Pahnke, 1969). This approach thus
differs from the use of psychoactive substances for
palliative sedation, such as potent benzodiazepines,
which are meant to relieve suffering by decreasing
patients’ conscious awareness (Maltoni et al., 2012).
Corroborating the initial phase of research
conducted in the mid-20th century, recent trials
of psychedelic-assisted psychotherapy for the
treatment of existential suffering have also reported
promising results. For example, Grob et al. (2011)
found that psychedelic-assisted psychotherapy
could help attenuate existential distress in 12 patients
with advanced-stage cancer. The researchers noted
statistically significant reductions in symptoms of
depression and anxiety at 1 and 3 months posttreatment and reported no serious adverse events.
Similarly, Gasser et al. (2014) evaluated the safety
and efficacy of psychedelic-assisted psychotherapy
in 12 patients with existential suffering due to
a life-threatening illness. They found significant
reductions in symptoms of anxiety and reported no
serious adverse events.
More recently, Griffiths et al. (2016)
evaluated psychedelic-assisted psychotherapy for
the treatment of existential distress in 51 patients
with life-threatening cancers. The researchers noted
significant decreases in symptoms of depression
and anxiety, increases across various indices
of well-being, and reported no serious adverse
events. Comparably, Ross et al. (2016) found that a
single, psychedelic-assisted psychotherapy session
produced significant reductions in end-of-life
anxiety and depression in 29 patients with lifethreatening cancers and reported no occurrences of
serious adverse events.
The promising recent findings of Grob et al.
(2011), Gasser et al. (2014), Griffiths et al. (2016),
and Ross et al. (2016) serve to further bolster the
initial phase of research implicating the utility
of psychedelic-assisted psychotherapy for those
experiencing psychological and existential suffering
at the end-of-life. The studies conducted by Griffiths
et al. (2016) and Ross et al. (2016) are particularly
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significant in that they are the largest, randomized
controlled trials of psilocybin to date. Critically,
these studies demonstrate that remarkable benefits
can be achieved from even a single administration.
The efficiency of this treatment modality is thus
particularly relevant for patients with life-threatening
illnesses who may not have the time to devote to a
lengthy course of therapy. However, perhaps most
importantly these studies demonstrate the safety of
using psilocybin in this patient population.
What is particularly interesting about these
studies is the significant association between the
occurrence of a psychedelic-induced mystical
experience and the most pronounced therapeutic
outcomes (Griffiths et al., 2016; Ross et al., 2016).
In fact, the participant-rated intensity of the mystical
experience statistically mediated therapeutic
improvements in both the Griffiths et al. (2016) and
Ross et al. (2016) studies. These findings correspond
with contemporary research using healthy
volunteers in which psychedelic-induced mystical
experiences predicted lasting positive changes in
attitudes, mood, behavior, and spirituality (Griffiths
et al., 2011; MacLean et al., 2011). They also parallel
historic findings in which palliative patients who
had a psychedelic-induced mystical experience
reported reduced despair, anxiety, and fear of
death, deepened relationships, and enhanced wellbeing (e.g., Grof & Halifax, 1977; Kurland, 1985;
Pahnke, 1967, 1969; Richards et al., 1977). To better
understand the salubrious effects of mystical states
and the role for psychedelic substances at the endof-life, we now turn to an overview of existential
suffering and self-transcendence.
Psychedelic-Assisted Self-Transcendence
and the Alleviation of Existential Suffering
Although suffering is often simply equated
with physical pain, the term does not connote
strictly physical determinants. Instead, suffering may
also stem from psychological, social, and existential
sources (Saunders, 1988). Suffering can thus be
viewed as a complex phenomenon involving an
aversive emotional state resulting from the loss, or
threatened loss, of the integrity of the individual (see
LeMay & Wilson, 2008). For example, Cassel (1982)
defines suffering as “the state of severe distress
associated with events that threaten the intactness

36

International Journal of Transpersonal Studies

of the person” (p. 640), while Kearney (2000)
views suffering as “the experience that results from
damage to the whole person” (p. 5).
Perhaps unsurprisingly, research suggests
that existential suffering is amongst the most
devastating forms of distress experienced by many
patients nearing the end-of-life, with some studies
indicating it is of patients’ greatest concern (Cassel
& Field, 1997; Greisinger et al., 1996). Indeed,
given that suffering occurs upon the experienced
or anticipated loss of part of one’s self or life,
awareness of approaching death—and with it the
ultimate loss of self—frequently evokes tremendous
despair (Yalom, 2008). Paul Tillich (1952) described
this awareness of one’s future non-existence as
ontological anxiety—the terror of death and the
loss of being. This distress is particularly evident
amongst individuals approaching end-of-life for
whom death is developmentally/normatively offtime (Weenolsen, 1988).
Due to growing awareness of its clinical
importance at the end-of-life, existential suffering
has garnered increased consideration over the
past few years (see LeMay & Wilson, 2008). In a
comprehensive review of the literature, Boston et
al. (2011) identified numerous conceptualizations
of existential suffering/existential distress, which
they view as a single conceptual entity. These
include existential pain (Strang et al., 2004), spiritual
despair (Edwards et al., 2010), existential distress
(Kissane, 2000), demoralization syndrome (Clarke
& Kissane, 2002), and spiritual distress (Caldeira et
al., 2013). Although these are not strictly analogous
constructs, Boston et al. (2011) noted that the core
symptom profile of this overarching syndrome
include the loss of meaning in life, hopelessness,
depression, a sense of being a burden, disturbance
in one’s connection to self, others, the world, or
the transcendent, isolation, anticipatory grief, and
death anxiety. Chochinov (2006) likewise suggested
that differentiating between these various terms and
conceptualizations is less critical than appreciating
the shared domain they address—the human need
to find a deep sense of meaning, connection, and
hope at the end-of-life.
Research has demonstrated that addressing
existential distress is crucial to enhancing quality
St. Arnaud

of life and well-being (Le May & Wilson, 2008).
For example, existential suffering can manifest in
debilitating physical symptoms, such as acute pain
(e.g., Chochinov, 2006), and may increase the desire
for a hastened death, even when physical symptoms
are effectively managed (Moss & Dobson, 2006).
Thus, Cohen et al. (1996) have argued that the role
of existential factors in patient well-being cannot
simply be reduced to physical or even psychosocial
determinants.
Yet, despite its relevance to end-of-life,
existential suffering remains a neglected area of care,
largely due to a lack of effective treatments (Boston
et al., 2011). Interestingly, Acton and Wright (2000)
and Cassel (1982) have argued that an intervention
designed to promote self-transcendence may help
to assuage existential suffering/distress. Indeed,
growing research in gerontology and palliative care
indicates that self-transcendence can help patients
achieve a sense of equanimity and acceptance
by adopting a broader transpersonal or cosmic
perspective towards life and death (see Reed, 2003;
Tornstam, 1989).
Conceptualizing Self-Transcendence
The field of transpersonal psychology has
long been concerned with personal transformation
and the important role of self-expansive, spiritual,
and mystical states of consciousness in human
well-being and development (Hartelius et al., 2013).
Transpersonal psychology has explicit origins in the
writings of William James (1902), who noted that
our ordinary, waking state of consciousness is but
one of many that we are capable of experiencing. In
addition to this waking state, various non-ordinary
states of consciousness can be obtained (Tart,
1975). Of these, self-transcendent states involve
a temporarily decreased awareness of self and,
simultaneously, increased feelings of connectedness,
belonging, and unity (Yaden et al., 2017).
Self-transcendent states are believed to
exist on a spectrum of intensity described as the
unitary continuum (Newberg & d’Aquili, 2000). At
the low end of the spectrum are positioned states
such as mindful awareness and flow, whereas in
the midrange fall the self-transcendent emotions,
such as awe. At the furthest end lies the mystical
experience which, as the most potent form of self-

transcendent state, usually involves complete selfdissolution, leaving the person feeling a sense of
unity with something greater than their personal self
(Hood, 2016).
Mystical experiences are typically felt to
be profoundly religious/spiritual in nature and
are a common component of numerous religious
traditions (Newberg & d’Aquili, 2000). In fact,
it has been argued that the mystical experience
may form the basis of human religion/spirituality
(Maslow, 1971). In such a way, religion/spirituality
is thought to be largely rooted in the natural,
human capacity for self-transcendent states of
consciousness (MacDonald et al., 2015), regardless
of the innumerable ways in which they may be
experienced and interpreted (Ferrer, 2011).
However, although the term selftranscendence has been used to describe temporary
mental states involving a decreased sense of self
and increased feelings of connectedness, the term
has also been used to describe a personality trait
or disposition (Yaden et al., 2017). In this regard,
self-transcendence may be defined as one’s general
sense of “connection to something higher—the
belief that there is meaning or purpose larger than
ourselves” (Peterson & Seligman, 2004, p. 48). Selftranscendence as a trait involves feelings of awe,
hope, and gratitude; it reminds us of how small
we are and gives us a sense of significance via
our inclusion within something larger (Peterson &
Seligman, 2004). Like self-transcendent states, selftranscendence as a trait is similarly intrinsic to human
nature and is not incumbent upon metaphysical
beliefs or dogmas of any kind (Elkins et al., 1988;
Streib & Hood, 2013). In other words, although selftranscendence is often expressed in religious or
spiritual terminology, it is universally accessible in
the awe-inspiring feeling of oneness and connection
with something beyond one’s personal self, such as
nature or the cosmos (Cassell, 1982).
Self-Transcendence as a Developmental Process
Although self-transcendence may be
viewed as a static trait, it can also be understood
developmentally, as a trait that steadily increases
over the course of adulthood (Levenson et al., 2005).
In such a way, self-transcendence entails a gradual
expansion of self-boundaries as well as the mature
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perspective that develops through this process (for
a review of self-transcendence, see Garcia-Romeu,
2010). Maslow (1971) argued that self-transcending
individuals have reached “the very highest and most
inclusive or holistic level of human consciousness,
behaving and relating, as ends rather than means,
to oneself, to significant others, to human beings
in general, to other species, to nature, and to the
cosmos” (p. 269).
Levenson et al. (2001) noted that experiences
of loss are integral to the developmental process
of self-transcendence. For example, normative
transitions from one “season” of life to another
require change, which invariably entails loss of
a former self-concept or identity (Marcia, 2010).
Similarly, with increasing age one gradually faces
the loss of friends, family, career, bodily functioning,
and so on. Although distressing, the experienced
loss of part of one’s self or life may foster hypohabituation and self-reflection, which can lead to
potential liberation from the constraints of a former
self-concept. This allows one sense of self to expand
in identification with a frame that goes beyond one’s
current self-boundaries (Levenson et al., 2001). Thus,
inasmuch as an individual is able to transcend a loss
by expanding his or her sense of self, a crisis can
be an opportunity for growth. Reed (2009) argued
that self-transcendence is the underlying process
mediating between an existential crisis—whether the
normative loss of a life transition or the traumatic loss
of some aspect of one’s life or self—and well-being.
As such, self-transcendence will—under
normative conditions—increase as one sustains,
mourns, and transcends losses over the course of
adulthood, thus slowly preparing the individual
to surmount the ultimate loss of self—one’s death
(Weenolsen, 1988). According to Erikson (1997),
without resolving this final developmental crisis,
an individual will experience existential suffering.
However, although Erikson (1997) believed that
resolution of this crisis required the development of
ego-integrity, Tornstam (1989) argued that it in fact
entails a heightened degree of self-transcendence.
Following Tornstam, Joan Erikson (1997) expanded
her husband’s eight-stage model by proposing that
there is indeed a ninth, self-transcendent stage of
development, entailing a shift from a rational and
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materialist perspective to a cosmic and transcendent
one. As one develops towards an ever more
pronounced degree of self-transcendence:
An impression of being One all together
becomes dominant. As a consequence, the
degree of self-centeredness will diminish. To a
certain extent, the enclosed self is disaggregated
and substituted with a cosmic self. Individuals
no longer look upon themselves as especially
important. They may perceive themselves as
part of a cosmic flow of energy, in which the
flow of energy, and not its parts is the important
thing. This also involves a redefinition of
the perception of life and death. It is not the
individual but rather the total flow of life that
is important. It is only logical then that the fear
of death will decrease while feelings of affinity
with past, present and future generations will be
enhanced. (Tornstam, 1989, p. 60)
Thus, in order to resolve the final
developmental crisis of death, one must transcend
his or her separate, personal self—one must
experience a sense of identification and oneness
with that which endures beyond death, whether
that be conceptualized as nature, the cosmos,
God, or some other transpersonal reality. Although
this maturation towards greater levels of selftranscendence typically develops over the course
of adulthood, it is not contingent upon age, and
may be accelerated (Reed, 1991; Tornstam, 1989).
For example, this might apply to a young woman
who finds herself with a terminal cancer diagnosis
at the age of 35. She must now prematurely resolve
the developmental crisis of death at an age that
is normatively off-time. Although this is a very
heavy burden, Marcia (2010) emphasized that
premature resolution of what are normatively later
developmental crises is possible.
Tomer and Eliason (2008) proposed that the
ideal therapeutic approach to existential suffering
associated with the crisis of death is a direct
experience of self-transcendence—a state of mystical
consciousness. As the most potent form of selftranscendent state, during a mystical experience the
individual entirely loses personal individuality in the
experience of ego-death, though retains conscious
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awareness in an experience of being part of a
reality greater than self (Pahnke, 1969). Through the
experienced loss of bodily, egoic, and social aspects
of identity, though retention of conscious awareness,
the person is enabled to directly experience him or
herself as a small facet of something much more
enduring that will continue beyond his or her death
(Hood & Morris, 1983). In other words, in the mystical
state it is possible to experience non-separation and
oneness with the fundamental ground of being,
regardless of how it is interpreted (Levenson et al.,
2001). Cassell (1982) noted that:

Thus, the ultimate fear is not of death itself,
but the sense of meaninglessness, disconnection,
and hopelessness it engenders (Weenolsen, 1991).
Yet, one need no longer despair after having
directly experienced him or herself as a part of a
vaster and more enduring reality. This is what Lifton
(1976) described as experiential transcendence in
the service of symbolic immortality. This sense of
immortality requires neither the denial of death
nor the belief in a personal afterlife, but rather
the maintenance of a sense of connection and
continuity with that which transcends death. This,
in turn, serves to buffer against death anxiety,
hopelessness, and meaningless (i.e., existential
suffering). Crucially, numerous studies have shown
that self-transcendence is a central predictor of wellbeing at the end-of-life, even after controlling for
other critical variables (for reviews see Coward &
Reed, 1996; Reed, 2009).
Psychedelic-Assisted Mystical Experiences
and the Development of Self-Transcendence
At this point a critical question becomes:
can psychedelic-facilitated mystical experiences
be harnessed to catalyze the process of selftranscendence at the end-of-life? In other words,
might psychedelic-assisted psychotherapy be used

to aid one’s liberation from the boundaries of the
personal self by inducing an experience of complete
self-dissolution (ego death) and subsequent selfexpansion (rebirth)? Previous findings strongly
suggest that they may.
For example, Pahnke (1967, 1969) found
that patients experienced the most dramatic
therapeutic effects in the wake of a psychedelic
mystical experience. Once an individual had a
mystical experience, life and death came to be
viewed from a new perspective. As the patient’s
personal sense of identity or self faded away, he or
she became aware of being part of something much
vaster and felt that “all is one.” The person was
able to approach the end of their life with a sense
of tranquility and a loss of despair, anxiety, and
fear of death. Pahnke noted that these therapeutic
outcomes were most pronounced upon complete
surrender to the experience of ego-loss and positive
self-transcendence, which is often experienced as a
moment of death and rebirth.
Similarly, Fisher (1970, 1972) found that
patients who had a psychedelic induced mystical
experience developed a new perspective towards
life and a reduced fear of death. Patients reported
that their sense of identity would often expand into a
sense of “oneness” with the unfolding process of life
or the universe. Fisher proposed that in the mystical
state, one directly experiences shared identity with
something extending beyond one’s physical self,
thereby reducing or eliminating death anxiety.
Richards (2009) has similarly described the
benefits of mystical experiences for patients at the
end-of-life. Richards noted that for patients who had
a psychedelic-induced mystical experience, fear of
death was replaced with a sense of curiosity and
trust, as the notion of eternity, a perspective outside
of space and time, and overwhelming love were
directly experienced in the mystical state. However,
the reality of physical death was not denied. Rather,
the continued existence of the individual self ceased
to be of chief relevance. For these patients, life came
to be seen through an expanded lens extending
beyond one’s personal existence, which attenuated
the fear of death, anxiety, depression, alienation,
and preoccupation with pain. These patients thus
became more integrated, better able to embrace the
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When experienced, transcendence locates the
person in a far larger landscape. The sufferer
is not isolated by pain but is brought closer to
a transpersonal source of meaning and to the
human community that shares those meanings.
Such an experience need not involve religion in
any formal sense; however, in its transpersonal
dimension, it is deeply spiritual.” (p. 644)
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remainder of their life, and more open to reconciling
with family members (Richards, 2009).
More recently, Swift et al. (2017) and
Malone et al. (2018) conducted follow-up interviews
with participants in the aforementioned Ross et al.
(2016) study. During their psilocybin sessions, many
participants reported an experienced loss of self
and feelings of connection/unity, the core facets
of a mystical state (Swift et al., 2017; Malone et al.,
2018). Importantly, this sense of ego-dissolution and
unity brought relief for many patients, with nearly
all participants noting the development of a new
understanding and acceptance of death and dying
(Swift et al., 2017). For example, one participant
reported that her psilocybin experience provided
“a greater understanding of global connectedness,”
noting that this sense of belonging helped to ease
her fear of death:
[The psilocybin] just opens you up and it
connects you... it’s not just people, it’s animals,
it’s trees—everything is interwoven, and that’s a
big relief... I think it does help you accept death
because you don’t feel alone, you don’t feel
like you’re going to, I don’t know, go off into
nothingness. That’s the number one thing—
you’re just not alone. (Swift et al., 2017, p. 499)
Another participant similarly reported
feelings of self-transcendent connection and unity
which also helped her to reconcile fears surrounding
death and dying:
I felt like this was really dealing with death... I’m
in the forest and there’s this beautiful, loamy,
woodsy, green, lush kind of woods, and I’m
down below the ground... And it felt really,
really good, and I thought, “That’s what happens
when you die. I am going to be reconnected
with this beautiful world. This earthy world that
we live in... It was just simple. It was gorgeous.
(Swift et al., 2017, p. 500)
Importantly, many participants noted that
these feelings of connectedness were not transient
but left an enduring self-transcendent perspective,
lasting well beyond the session. For example,
one participant reported, “I was the cloud, I was
everything, and that was the theme throughout
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the whole [experience], that I was all this—this
was me. And it was so wonderful... to believe that.
And I still do—that is me” (Malone et al., 2018, p.
5). Furthermore, she felt as if she experienced her
own death (ego-death) on two occasions during the
experience and emerged both unafraid and viewing
it as an integral part of existence. She noted, “I was
just part of this big beautiful world ... and that’s
what’s going to happen when I die ... maybe death
is a beautiful thing” (Malone et al., 2018, p. 5).
It is clearly evident that the patients’ attitudes
and perspectives fostered by the psychedelic
experiences as reported by Pahnke (1967, 1969),
Fisher (1970, 1972), Richards (2009), Swift et al.
(2017), and Malone et al. (2018) closely resemble
descriptions of self-transcendence in the palliative
care and gerontology literature, such as noted
by Tornstam (1989). This strong correspondence
suggests that, when judiciously utilized, psychedelics
may help further catalyze the developmental shift to
a self-transcendent metaperspective. In other words,
mystical experiences—as a temporary state of selftranscendence—may help facilitate the development
of a more enduring self-transcendent trait (Yaden
et al., 2017). By providing a direct experience of
pronounced self-transcendence, this mystical state
of consciousness could thus help patients resolve the
final development crisis, thereby reducing existential
distress as one approaches the end of life.
However, the complex interrelation of states
and traits remains a point of contention (see Wilber,
2006). It must be emphasized that a temporary,
self-transcendent state cannot be considered
synonymous with an enduring, self-transcendent
trait. Whereas traits are “consistent and stable
modes of an individual’s adjustment to his [or her]
environment,” states may be viewed as “present
activity, temporary states of mind, and mood”
(Allport & Odbert, 1936, p. 26). Nonetheless, an
enduring question in psychology has been: can
the occurrence of temporary states lead to the
development of enduring traits? Growing research
suggests that this question can now be answered in
the affirmative.
From a neurological standpoint, it has
been argued that temporary activation of neural
networks can lead to neuroplastic changes in
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brain structure and functioning (Cahn & Polich,
2006; Garland et al., 2010). For example, Holzel
et al. (2011) have documented neuroscientific
evidence that mindfulness practice (inducing
temporary states of mindfulness) can lead to
changes in brain functioning associated with
heightened trait mindfulness. Similarly, Kiken et
al. (2015) demonstrated that induction of states of
mindfulness via meditation practice can lead to
increases in trait mindfulness. These studies support
the argument made by Levenson and colleagues
(2005) that it is possible to foster the development
of a self-transcendent perspective (trait) through
intentional induction of self-transcendent states via
practices such as meditation. Furthermore, CarhartHarris and Nutt (2017) proposed that 5-HT2A
activation by the classic psychedelics modulates
neuropsychological change, citing evidence that
enhanced 5-HT2A signaling produces a state of
neuropsychological plasticity (see Carhart-Harris &
Nutt, 2017 for references). Similarly, Brouwer and
Carhart-Harris (2020) provide a compelling review
of the literature suggesting that radical, rapid, and
discrete neuropsychological transformation can
occur through activation of 5-HT2A signalling.
Taken together, these findings suggest
that experiencing acute states may indeed lead
to the development of more enduring changes in
traits. Nonetheless, just because one experiences
a powerful self-transcendent state it does not
follow that an enduring self-transcendent trait will
by default be carried over into one’s life. Sidney
Cohen argued that the psychedelic experience “is
not a spiritual labor-saving device, salvation, instant
wisdom, or a shortcut to maturity. However, it can
be an opportunity to experience oneself and the
world in new ways—and to learn from it” (1967, p.
1). Thus, although psychedelics can produce selftranscendent states with profound import, they
must be integrated to have lasting developmental
implications, which requires deliberate reflection
(Richards, 2016). In such a way, transpersonally
oriented, psychedelic-assisted psychotherapy may
be understood as a modality which helps patients
experience and cultivate a self-transcendent
perspective, thus helping them navigate life’s final
developmental crisis.

Considerations for the Safe and Ethical Application
of Psychedelic Substances
The Western cultural bias against
psychedelics has not only maligned the academic
study of these agents but has made it difficult to take
a balanced view of their relative harms and benefits
(Hood et al., 2009). As a result, over the past 50
years, the use of psychedelic drugs as an adjunct to
psychotherapy has remained a highly controversial
and polarizing area of inquiry (Nichols, 2016). This
is, at least to some extent, due to the historic abuses
that have been committed with these substances.
Although the therapeutic potential of psychedelic
compounds is well documented, it must be equally
acknowledged that these drugs have been used
in highly unethical ways. For example, the United
States military and CIA investigated the properties of
psychedelic drugs in highly unethical experiments
as agents of warfare and mind-control (see Collins,
1988; Grinspoon & Bakalar, 1979).
Although shameful to acknowledge, this
period of research sheds light on contemporary
societal fears of these drugs (Dyck, 2008).
Highlighting both the beneficent and malevolent
ends to which psychedelics may be applied illustrates
that they are simply chemical tools. This must be
emphasized, as it is ultimately the intentions, values,
and structures guiding their use that determines the
nature of the outcomes. Just as a scalpel may be
used to incise a cancerous tumor or inflict grievous
bodily harm, psychedelic compounds may also
be used for good or for ill. With both a scalpel or
psychedelic, however, it is not the tool itself which
is to blame—or praise—but rather, the intent, skill,
and maturity of the individual applying it. In such a
way, one might consider the current ban on the use
of psychedelics in mental healthcare as akin to a
ban on the use of scalpels in surgery.
Nonetheless, with the resurgence of
psychedelic research, and growing likelihood of their
eventual re-legalization and use in psychotherapy (see
Emerson et al., 2014), proper consideration of how to
guarantee the ethical application of these substances
will be paramount. The foremost way in which to
ensure patient safety will be the establishment of
rigorous protocols for both training psychedelicpsychotherapists and screening prospective patients.
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Psychedelic-Psychotherapists
To optimize patient care and safety it
will be imperative for clinicians to acknowledge
the limits of their expertise and utilize specialist
services in the application of this modality. As with
all pharmacological agents, medical or nursing
professionals will likely be required to oversee the
administration of psychedelic substances to ensure
the physical safety of patients.
However, as previously noted, psychedelics
are typically not used as a pharmacotherapy, but
rather to precipitate a state of consciousness that
catalyzes the therapeutic process. As a result,
great consideration will be required to choose the
psychotherapists who will conduct the therapy
itself, as patients under the influence of psychedelics
are exceptionally open to environmental influences
(Friedman, 2006). Issues of patient vulnerability,
suggestibility, and relational power dynamics take
on even greater significance in psychedelic-assisted
psychotherapy. Psychedelic psychotherapists require
a particularly high degree of psychological and
spiritual development, emotional maturity, and
ethical integrity to work judiciously with these
compounds (Grob, 2007).
Eisner (1997) argued that the capacity for
empathy, a decisively nonjudgmental attitude, great
patience, and openness of the “mind and heart” are
essential qualities for a psychedelic psychotherapist.
Phelps (2017) has likewise suggested that therapists
utilizing psychedelics must have a pronounced
degree of spiritual intelligence to work safely with
these substances. In a similar way, Sinnott (2000)
argued that any therapist working with transpersonal
content must be at a postconventional level of egodevelopment to avoid unskilled interventions that
could lead to the traumatic loss of part of a patient’s
self that may, for example, emerge in a psychedelic
experience. At this time, both spiritual intelligence
and ego-development can be assessed with validated
psychometric scales (e.g., Hy & Loevinger, 1996;
King & DiCicco, 2009). Perhaps these measures, or
something similar to them, would be useful in the
training or selection of psychedelic psychotherapists.
Beyond the requisite psychological and
spiritual maturity, specialized training will also be
required to be competent in psychedelic-assisted
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psychotherapy. Training programs involving didactic,
practical, and experiential training are currently being
established by the Multidisciplinary Association for
Psychedelic Studies and the California Institute of
Integral Studies, amongst others (see Emerson et al.,
2014; Phelps, 2017). At this time, potential trainees
are required to be licensed medical or mental health
professionals or clergy/chaplains who have had
sufficient psychiatry, psychology, psychotherapy,
or pastoral counseling training (Phelps, 2017). It
has been suggested that first-hand experience with
psychedelics should be included as part of training,
as the capacity to safely guide others through a
psychedelic sojourn is believed to require personal
experience in these realms (Eisner, 1997).
Given that individuals may find religious
or spiritual terminology most appropriate to
describe their psychedelic experiences (Masters &
Houston, 1966), spiritual professionals may be of
tremendous assistance to help patients integrate
these experiences. When used to foster a spiritual
experience, psychedelics may even qualify as
sacraments, defined as that “through which the
holy makes its presence felt” (Dourley, 1981, p.
31). In discussing logotherapy, Frankl (1963) noted
that it “does not cross the boundary between
psychotherapy and religion. But it leaves the door to
religion open and it leaves it to the patient whether
or not to pass the door” (p. 143). In the same way,
psychedelic psychotherapists must not proselytize,
as imposing beliefs and values on patients is a breach
of ethical standards. Following the participatory turn
(Ferrer, 2011), psychedelic psychotherapists must
hold an open, diverse, and multi-focal perspective
towards spirituality to ensure that patient’s beliefs
and spiritual trajectories are honored.
Psychedelic Patients
It will also be essential to have frameworks
in place that help distinguish those patients most
likely to benefit from those most likely to be harmed.
As previously noted, psychedelic substances can be
used in demonstrably therapeutic ways, but may
also cause psychosis-like reactions or even trigger
the onset of a psychotic disorder in predisposed
individuals.
In a recent synthesis, Swanson (2018)
reviewed the major psychedelic theories from
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the 19th, 20th, and 21st centuries, and presented
four areas on which they all converge: 1) psychedelics produce their effects by inhibiting the
neuropsychological mechanisms which normally
constrain consciousness; 2) too much or too little
constraint can contribute to psychopathology;
3) psychedelic effects may appear similar to
psychotic symptoms because both involve
inhibited constraints; and 4) psychedelic drugs
are therapeutically useful precisely because they
inhibit these constraints. Thus, psychedelics may
be viewed as the quintessential pharmakon, at once
both a potential remedy or poison (cf. Meier, 1967).
Consequently, it follows that while
for some individuals the relaxation of these
neuropsychological constraints is potentially
dangerous, for others it is potentially advantageous.
Developmental psychopathology, in tandem with
adult developmental and transpersonal psychology,
may be helpful in aiding a delineation. Extensive
research in this area has shown that psychotic
illnesses do not simply emerge de novo, but rather,
have a developmental trajectory. In other words,
schizophrenia and related psychotic disorders are
the outcome of numerous aberrations and deficits
in development over time. Thus, a psychotic-like
psychedelic experience in an otherwise healthy
individual does not imply that one is now psychotic
or will necessarily develop a psychotic disorder (St.
Arnaud & Cormier, 2017).
Furthermore, according to adult developmental/transpersonal theory, the extent to which
an individual may benefit, or be harmed, from
non-ordinary states differs according to their
developmental maturity (Cook-Greuter, 2000).
Wilber’s (2006) notion of the pre/trans distinction
suggests that for individuals on a deleterious
developmental pathway, self-dissolution via psychedelics may precipitate a pathological opening to
the prerational—a regressive movement towards
psychosis. Because psychedelic experiences can be
highly destabilizing, they may trigger a psychotic
response in such individuals, as they do not have the
necessary self-structure to tolerate intense primary
process affect, fantasy, or imagery (Cortright, 2007),
and thus may lose their hold on reality testing. In a
similar way, psychoanalysts refer to lacunae or holes

in the self-structure of those who have a psychotic
disorder or are on a trajectory towards developing
one (Harter, 2016).
Conversely, Nelson and Sass (2008)
pointed out that although disruption in one’s sense
of self may induce pathological disruptions in
those with, or prone to, psychotic disorders, the
very same process can precipitate a beneficial
mystical experience in others. In contrast to the
potential for psychotic decompensation in those
on a deleterious developmental pathway, healthy
adult development involves movement from
conventional into postconventional bands of ego
maturity and beyond (Irwin, 2002). Individuals at
these levels of development are able to deliberately
and safely deconstruct self-boundaries, as they
have developed the prerequisite ego stability to
differentiate prepersonal from transpersonal material
(Cook-Greuter, 2000). In other words, one must
have established a stable self-structure before it can
be safely transcended. For individuals on a healthy
developmental pathway, self-dissolution may
precipitate a non-pathological opening to the transrational or transpersonal. In such cases, inhibition
of the normal constraints on consciousness with
the aid of psychedelics may lead to ecstatic (though
potentially frightening) self-dissolution and mystical
union.
Psychedelics and Surrender
Fahlberg et al. (1992) cautioned that selftranscendence requires the individual to first
surrender a former self-concept to achieve an
expanded sense of self and noted that this form of
transpersonal awareness can be distressing. Indeed,
self-transcendence requires that we must first accept
loss; to disidentify from a former self-concept, one
must experience a type of ego loss (or death) and the
associated feelings of grief. Stein (2004) argued that
the inherent desire for self-transcendence involves a
venture into the unknown—that which annihilates
the ego. In other words, one first must “let go” of,
or mourn, an aspect of self or identity before one
can be reborn in a more integrated and expansive
self. Given that one may encounter psychodynamic
strata of the mind as a result of this ego-dissolution,
such as unresolved intra- and interpersonal conflicts
and repressed traumatic memories (Richards,
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2016), the patient must be open to, and capable of
integrating, this material.
Indeed, it has been noted since the early
period of psychedelic research in the mid-20th
century that deliberately surrendering control to
whatever arises in the psychedelic state is crucial for
a positive experience (Leary et al., 2007). From the
perspective of the patient, it is essential that he or
she have a serious, conscious intention of “letting
go” to whatever arises (Eisner, 1997). Richards
(2016) argued that fear and psychotic-like features
emerge when one is unable to trust the process and
desperately strives to maintain control.
The importance of surrender or acceptance
is witnessed in Swift et al.’s (2017) qualitative study.
Many patients reported that their psychedelic
experience initially felt overwhelming, challenging,
or fearful, noting that the difficulty was linked to
fears of losing control. One participant reported, “I
was watching everything disintegrate ... my past, my
relationships, my personality, everything that makes
me feel like [me] ... That was terrifying” (Swift et al.,
2017, p. 497). However, when participants were able
to surrender and accept the experience, the intensity
abated, leading to feelings of calmness and peace.
Thus, the desire for self-dissolution and selftranscendence must be entered into intentionally
(Levenson et al., 2001). Sundararajan (2002) also
proposed that one of the key differences between
whether an encounter with the numinous will be
experienced as awe-full or awe-some is the desire
of the individual to surrender to the experience,
to deliberately and receptively allow their self to
be dissolved and absorbed into something greater.
In other words, both the desire and the requisite
maturity for self-transcendence.
Thus, one must be able to distinguish which
patients will have adaptive though potentially
challenging experiences of self-loss and corresponding
self-expansion from those who will have pathological
self-loss and psychotic decompensation. To do
so, one must assess the developmental history of
the patient to understand the potential effects of
inhibiting the normal constraints on consciousness.
As a basic guideline, patients with cognitive and
emotional conditions associated with diminished ego
strength are typically not appropriate for psychedelic-
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assisted psychotherapy (Byock, 2018). In other
words, perhaps only patients within conventional
and postconventional levels of ego functioning have
the requisite psychological stability to safely dissolve
their self-structure with the aid of psychedelics (cf.
Irwin, 2002). In order to assess this dimension as
a screening index, it may be advantageous for
clinicians to utilize an assessment measure such as
the Washington University Sentence Completion Test
(Hy & Loevinger, 1996) which was designed to assess
ego-development.
Philosophical Considerations
Despite evidence that psychoactive
substances played a role in various Judeo-Christian,
Islamic, and other religious sects (see Hood et al.,
2009 for references), some individuals may object
to the use of psychedelics on religious grounds
by arguing that using psychoactive substances to
induce spiritual experiences is either impossible
or sacrilegious. However, the similarity between
the psychedelic compounds found within plants,
animals, and naturally within the human brain
suggests that any delineation between natural and
artificially generated experience, drug induced or
otherwise, is arbitrary (Weil, 1986). Relatedly, some
may take offense at the attempt to explain profound
spiritual experiences using reductive language.
However, understanding how our eyes receive
wavelengths of light which are then processed
into visual experiences does not detract from
the experienced poignancy of a beautiful sunset
(Goodman, 2002). In much the same way, explaining
the biochemical pathways by which spiritual
experiences are mediated need not detract from the
profundity, or even veracity, of the experience itself
(James, 1902).
Science can neither confirm nor deny the
existence of metaphysical or divine realities based on
phenomenological accounts of mystical experiences
(Shafranske & Sperry, 2005). It can, however, study
these experiences without accepting them as
revealing ontological truths. Most importantly, it can
study the tangible outcomes of these experiences—
that is, William James’s (1902) fruits of religious
experience (Hood et al., 2009). Although science
must remain agnostic on the metaphysical veracity
of psychedelic induced mystical experiences, if
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nothing else it can and should study their potential
contribution to well-being and flourishing.
Nonetheless, the robust empirical finding
that the therapeutic effects of psychedelics often
derive from the mystical experiences they can induce
presents a challenge to contemporary notions about
the role of spirituality in healthcare. More than half a
century ago Pahnke and Richards (1966) noted that the
use of psychedelics to induce mystical experiences
was problematic for those health professionals who
prided themselves on their “scientific objectivity.”
However—perhaps somewhat ironically—it is
precisely because psychedelics can evoke these
states of consciousness under controlled conditions
that they hold remarkable import for the scientific
study of spiritual experiences and their clinical
value. In this sense, psychedelics represent a critical
tool for the continued development of transpersonal
psychology and psychotherapy.
However, although it is essential to have
a scientific appreciation and understanding of
these drugs and the experiences they can induce,
this must not diminish or otherwise reduce the
importance of the phenomenology itself. Bradshaw
(1996) raised an important point of concern when
she questioned whether biomedical technology—
though enhancing treatment—may at times overmedicalize our humanity. She cautioned that the
spiritual ideal at the core of palliative care must not
be rationalized away. Echoing Bradshaw’s warning,
it is equally imperative that the use of psychedelics to
foster transformative self-transcendent experiences
not be diminished or merely explained away.
We must accept that psychedelics are more than
material objects with physiological effects; they
hold meanings and shape social discourse as they
evolve through the conjunction of individuals in
society (Montagne, 1996).
Similarly, Chochinov (2006) argued that
there is a substantial difference between the
mechanistic application of a treatment and a truly
holistic approach to care that accepts and gives
credence to the totality of the person—biological,
psychosocial, and existential-spiritual. Psychedelicinduced physiological changes and psychedelicinduced spiritual experiences need not be considered
mutually exclusive. Rather, they may be viewed as

complementary ways of understanding the same
process. By approaching psychedelics holistically—
not only as potent serotonin agonists but also as
spiritual medicines or even sacraments—perhaps an
attitude guarding against an overly mechanistic and
bureaucratic approach to their use can be instilled.
Conclusion
It has been said that we are in the midst of
a psychedelic renaissance. The word renaissance
derives from the French, to be born again, and
refers to the recovery of culture, skills, learning,
or knowledge that had been forgotten (Shafranske
& Sperry, 2005). Given that humans have used
psychedelics for millennia for therapeutic and
spiritual purposes, the burgeoning study of
these substances truly qualifies for this label. In
fact, psychedelic-assisted psychotherapy may
be considered a transpersonal “therapy directly
or indirectly concerned with the recognition,
acceptance, and realization of ultimate states. As
such, it is not new; rather it is perhaps the oldest of
all the therapeutic approaches” (Sutich, 1973, p. 3).
Indeed, as this article has sought to highlight,
psychedelic-assisted psychotherapy is a promising
renascent treatment that may—in particular—afford
clinicians with an invaluable option to alleviate
existential suffering amongst those approaching
the end-of-life. Although psychedelic-assisted
psychotherapy will not be a panacea for all
individuals, given the severity of existential distress
and lack of effective treatment options currently
available (Boston et al., 2011; Gasser et al., 2015),
surely this modality bears our serious consideration.

Psychedelic-Assisted Self-Transcendence at End-of-Life

International Journal of Transpersonal Studies

References
Acton, G. J., & Wright, K. B. (2000). Self-transcendence
and family caregivers of adults with dementia.
Journal of Holistic Nursing, 18, 143–158.
Allport, G. W., & Odbert, H. S. (1936). Trait
names: A psycho-lexical study. Psychological
Monographs, 47(1, Whole No. 211).
Bogenschutz, M. P., & Johnson, M. W. (2016). Classic
hallucinogens in the treatment of addictions.
Progress in Neuro-Psychopharmacology and
Biological Psychiatry, 64, 250–258. https://doi.
org/10.1016/j.pnpbp.2015.03.002

45

Boston, P., Bruce, A., & Schreiber, R. (2011).
Existential suffering in the palliative care setting:
An integrated literature review. Journal of Pain
and Symptom Management, 41, 604–618. https://
doi.org/10.1016/j.jpainsymman.2010.05.010
Bradshaw, A. (1996). The spiritual dimension of
hospice: The secularization of an ideal. Social
Science & Medicine, 43, 409–419. https://doi.
org/10.1016/0277-9536(95)00406-8
Brouwer,A.,&Carhart-Harris,R.L.(2020).Pivotalmental
states. Journal of Psychopharmacology, 35(4), 319–
352. https://doi.org/10.1177/0269881120959637
Byock, I. (2018). Taking psychedelics seriously.
Journal of Palliative Medicine, 21, 417–421.
https://doi.org/10.1089/jpm.2017.0684
Cahn, B. R., & Polich, J. (2006). Meditation states
and traits: EEG, ERP, and neuroimaging studies.
Psychological Bulletin, 132, 180–211. https://doi.
org/10.1037/0033-2909.132.2.180
Caldeira, S., Carvalho, E. C., & Vieira, M. (2013).
Spiritual distress—Proposing a new definition
and defining characteristics. International
Journal of Nursing Knowledge, 24, 77–84.
Canal, C. E., & Murnane, K. S. (2017). The serotonin
5-HT2C receptor and the non-addictive
nature of classic hallucinogens. Journal of
Psychopharmacology, 31, 127–143. https://doi.
org/10.1177/0269881116677104
Carhart-Harris, R. L., Erritzoe, D., Williams, T.,
Stone, J. M., Reed, L. J., Colasanti, A., Tyacke,
R. J., Leech, R., Malizia, A. L., Murphy, K., &
Hobden, P. (2012). Neural correlates of the
psychedelic state as determined by fMRI studies
with psilocybin. Proceedings of the National
Academy of Sciences, 109, 2138–2143. https://
doi.org/10.1073/pnas.1119598109
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M.,
Williams, T. M., Williams, L. T., Underwood, R.,
Feilding, A., & Nutt, D. J. (2016). The paradoxical
psychological effects of lysergic acid diethylamide
(LSD). Psychological Medicine, 46, 1379–1390.
https://doi.org/10.1017/S0033291715002901
Carhart-Harris, R. L., Leech, R., Hellyer, P. J.,
Shanahan, M., Feilding, A., Tagliazucchi, E.,
Chialvo, D. R., & Nutt, D. (2014). The entropic
brain: A theory of conscious states informed by
neuroimaging research with psychedelic drugs.

46

International Journal of Transpersonal Studies

Frontiers in Human Neuroscience, 8, 1–22.
https://doi.org/10.3389/fnhum.2014.00020
Carhart-Harris, R. L., & Nutt, D. J. (2017). Serotonin
and brain function: a tale of two receptors.
Journal of Psychopharmacology, 31, 1091–1120.
https://doi.org/10.1177/0269881117725915
Cassel, C. K., & Field, M. J. (1997). Approaching
death: Improving care at the end of life. National
Academies Press.
Cassell, E. J. (1982). The nature of suffering and
the goals of medicine. New England Journal
of Medicine, 306, 639–645. https://doi.
org/10.1056/NEJM198203183061104
Chaplin, W. F., John, O. P., & Goldberg, L. R. (1988).
Conceptions of states and traits: Dimensional
attributes with ideals as prototypes. Journal of
Personality and Social Psychology, 54, 541–557.
Chochinov, H. M. (2006). Dying, dignity, and new
horizons in palliative end-of-life care. CA: A
Cancer Journal for Clinicians, 56, 84–103. https://
doi.org/10.3322/canjclin.56.2.84
Chochinov, H. M., Kristjanson, L. J., Breitbart, W.,
McClement, S., Hack, T. F., Hassard, T., &
Harlos, M. (2011). Effect of dignity therapy on
distress and end-of-life experience in terminally
ill patients: A randomised controlled trial. The
Lancet Oncology, 12, 753–762.
Clarke, D. M., & Kissane, D. W. (2002). Demoralization: Its phenomenology and importance.
Australian and New Zealand Journal of
Psychiatry, 36, 733–742.
Cohen, S. (1985). LSD: The varieties of psychotic
experience. Journal of Psychoactive Drugs, 17,
291–296. https://doi.org/10.1080/02791072.198
5.10524333
Cohen, S. R., Mount, B. M., Tomas, J. J., & Mount, L.
F. (1996). Existential well-being is an important
determinant of quality of life: Evidence from the
McGill Quality of Life questionnaire. Cancer, 77,
576–586.
Collins, A. (1988). In the sleep room: The story of
CIA brainwashing experiments in Canada. Lester
& Orpen Dennys.
Cook-Greuter, S. R. (2000). Mature ego development:
A gateway to ego transcendence? Journal of
Adult Development, 7, 227–240. https://doi.
org/10.1023/A:1009511411421
St. Arnaud

Cortright, B. (2007). Integral psychology: Yoga,
growth, and opening the heart. State University
of New York Press.
Coward, D. D., & Reed, P. G. (1996). Selftranscendence: A resource for healing at the
end of life. Issues in Mental Health Nursing, 17,
275–288.
https://doi.org/10.3109/016128496
09049920
Dourley, J. P. (1981). Psyche as sacrament: A
comparative study of C. G. Jung and Paul Tillich.
Inner City Books.
Dyck, E. (2008). Psychedelic psychiatry: LSD from
clinic to campus. JHU Press.
Edwards, A., Pang, N., Shiu, V., & Chan, C. (2010).
The understanding of spirituality and the
potential role of spiritual care in end-of-life
and palliative care: A meta-study of qualitative
research. Palliative Medicine, 24, 753–770.
Eisner, B. (1997). Set, setting, and matrix. Journal of
Psychoactive Drugs, 29, 213–216.
Elkins, D. N., Hedstrom, L. J., Hughes, L. L., Leaf, J.
A., & Saunders, C. (1988). Toward a humanisticphenomenological
spirituality:
Definition,
description, and measurement. Journal of
Humanistic Psychology, 28, 5–18. https://doi.
org/10.1177/0022167888284002
Emerson, A., Ponté, L., Jerome, L., & Doblin, R.
(2014). History and future of the Multidisciplinary Association for Psychedelic Studies
(MAPS). Journal of Psychoactive Drugs, 46,
27–36. https://doi.org/10.1080/02791072.2014.
877321
Erikson, J. M. (1997). The life cycle completed:
Extended version with new chapters on the
ninth stage of development. W. W. Norton .
Fahlberg, L., Wolfer, J., & Fahlberg, L. (1992).
Personal crisis: Growth or pathology? American
Journal of Health Promotion, 7, 45–52. https://
doi.org/10.4278/0890-1171-7.1.45
Ferrer, J. N. (2011). Participatory spirituality and
transpersonal theory: A ten-year retrospective.
Journal of Transpersonal Psychology, 43, 1–34.
Fisher, G. (1970). Psychotherapy for the dying:
principles and illustrative cases with special
reference to the use of LSD. OMEGA-Journal
of Death and Dying, 1, 3–15. https://doi.
org/10.2190/YH2E-R6MC-N8MQ-0TR5

Fisher, G. (1972). Death, identity, and creativity.
OMEGA-Journal of Death and Dying, 2, 303–
306. https://doi.org/10.2190/BBJ9-77QH-R13LAQNT
Frankl, V. (1963). Man’s search for meaning: An
introduction to logotherapy. Pocket Books.
Friedman, H. (2006). The renewal of psychedelic
research: Implications for humanistic and
transpersonal psychology. The Humanistic
Psychologist, 34, 39–58. https://doi.org/10.120
7/s1547333thp3401_5
Frood, A. (2006). Cluster busters. Nature Medicine,
13, 10–11. https://doi.org/10.1038/nm0107-10
Gable, R. S. (2004). Comparison of acute lethal
toxicity of commonly abused psychoactive
substances. Addiction, 99, 686–696. https://doi.
org/10.1111/j.1360-0443.2004.00744.x
Garcia-Romeu, A. (2010). Self-transcendence as a
measurable transpersonal construct. Journal of
Transpersonal Psychology, 42, 26–47.
Garland, E. L., Fredrickson, B., Kring, A. M., Johnson,
D. P., Meyer, P. S., & Penn, D. L. (2010). Upward
spirals of positive emotions counter downward
spirals of negativity: Insights from the broadenand-build theory and affective neuroscience
on the treatment of emotion dysfunctions and
deficits in psychopathology. Clinical Psychology
Review, 30, 849–864.
Gasser, P., Holstein, D., Michel, Y., Doblin, R.,
Yazar-Klosinski, B., Passie, T., & Brenneisen,
R. (2014). Safety and efficacy of lysergic acid
diethylamide-assisted psychotherapy for anxiety
associated with life-threatening diseases.
Journal of Nervous and Mental Disease, 202,
513–520. https://doi.org/10.1097/NMD.00000
00000000113
Gasser, P., Kirchner, K., & Passie, T. (2015). LSDassisted psychotherapy for anxiety associated
with a life-threatening disease: A qualitative
study of acute and sustained subjective effects.
Journal of Psychopharmacology, 29, 57–68.
https://doi.org/10.1177/0269881114555249
Goodman, N. (2002). The serotonergic system and
mysticism: Could LSD and the nondrug-induced
mystical experience share common neural
mechanisms? Journal of Psychoactive Drugs, 34, 263–
272. https://doi.org/10.1080/02791072.2002.10399962

Psychedelic-Assisted Self-Transcendence at End-of-Life

International Journal of Transpersonal Studies

47

Greisinger, A. J., Lorimor, R. J., Aday, L. A., Winn,
R. J., & Baile, W. F. (1996). Terminally ill cancer
patients. Their most important concerns. Cancer
Practice, 5, 147–154.
Griffiths, R. R., Johnson, M. W., Carducci, M. A.,
Umbricht, A., Richards, W. A., Richards, B.
D., Cosimano, M. P. and Klinedinst, M. A.
(2016). Psilocybin produces substantial and
sustained decreases in depression and anxiety
in patients with life-threatening cancer: A
randomized double-blind trial. Journal of
Psychopharmacology, 30, 1181–1197. https://doi.
org/10.1177/0269881116675513
Griffiths, R. R., Johnson, M. W., Richards, W.
A., Richards, B. D., McCann, U., & Jesse, R.
(2011). Psilocybin occasioned mystical-type
experiences: Immediate and persisting doserelated effects. Psychopharmacology, 218, 649–
665. https://doi.org/10.1007/s002130112358-5
Grinspoon, L., & Bakalar, J. B. (1979). Psychedelic
drugs reconsidered. Basic Books.
Grob, C. S. (2007). The use of psilocybin in
patients with advanced cancer and existential
anxiety. In M. J. Winkelman & T. B. Roberts
(Eds.), Psychedelic medicine: New evidence for
hallucinogenic substances as treatments (pp.
205–216). Praeger.
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty,
M., McKay, C. R., Halberstadt, A. L., & Greer, G.
R. (2011). Pilot study of psilocybin treatment for
anxiety in patients with advanced-stage cancer.
Archives of General Psychiatry, 68, 71–78. https://
doi.org/10.1001/archgenpsychiatry.2010.116
Grof, S. (1980). LSD psychotherapy. Hunter House.
Grof, S., Goodman, L. E., Richards, W. A., & Kurland,
A. A. (1973). LSD-assisted psychotherapy in
patients with terminal cancer. International
Pharmacopsychiatry, 8, 129–144. https://doi.
org/10.1159/000467984
Grof, S., & Halifax, J. (1977). The human encounter
with death. E. P. Dutton.
Halberstadt, A. L. (2015). Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.
Behavioural Brain Research, 277, 99–120.https://doi.
org/10.1016/j.bbr.2014.07.016
Harter, S. (2016). Developmental and prosocial
dimensions of hypo-egoic phenomena. In K.

48

International Journal of Transpersonal Studies

W. Brown & M. R. Leary (Eds.), The Oxford
handbook of hypo-egoic phenomena (pp. 79–
94). Oxford University Press.
Hartelius, G., Rothe, G., & Roy, R. J. (2013). A
brand from the burning. In H. L. Friedman & G.
Hartelius (Eds.) The Wiley-Blackwell handbook
of transpersonal psychology (pp. 3–22). Wiley
Blackwell.
Hartogsohn, I., (2017). Constructing drug effects: A
history of set and setting. Drug Science, Policy
& Law 3, 1–17.
Hendricks, P. S., Clark, C. B., Johnson, M. W.,
Fontaine, K. R., & Cropsey, K. L. (2014).
Hallucinogen use predicts reduced recidivism
among substance-involved offenders under
community corrections supervision. Journal of
Psychopharmacology, 28, 62–66. https://doi.
org/10.1177/0269881113513851
Hood, R. W. (2016). Mysticism and hypo-egoicism.
In K. W. Brown & M. R. Leary (Eds.), The Oxford
handbook of hypo-egoic phenomena (pp. 285–
296). Oxford University Press.
Hood, R. W., Hill, P. C., & Spilka, B. (2009). The
psychology of religion: An empirical approach.
Guilford Press.
Hood, R. W., & Morris, R. J. (1983). Toward a
theory of death transcendence. Journal for the
Scientific Study of Religion, 22, 353–365. https://
doi.org/10.2307/1385773
Holzel, B. K., Lazar, S. W., Gard, T., SchumanOlivier, Z., Vago, D. R., & Ott, U. (2011). How
does mindfulness meditation work? Proposing
mechanisms of action from a conceptual
and neural perspective. Perspectives on
Psychological Science, 6, 537–559.
Hy, L. X., & Loevinger, J. (1996). Measuring ego
development. L. Erlbaum Associates.
Irwin, R. R. (2002). Human development and
the spiritual life: How consciousness grows
toward transformation. Kluwer Academic/
Plenum. https://doi.org/10.1007/978-1-4615-06
57-7
Jaffe, J. H. (1990). Drug addiction and drug abuse.
In A. G. Goodman, T. W. Rall, A. S. Nies, &
P. Taylor (Eds.), Goodman & Gilman’s: The
pharmacological basis of therapeutics (pp. 522–
573). McGraw-Hill.
St. Arnaud

James, W. (1902). The varieties of religious
experience: A study in human nature. Modern
Library. https://doi.org/10.1037/10004-000
Johansen, P. Ø. (2013). Psychedelics and mental
health: A population study. PLoS One, 8, 1–9.
Johnson, M. W., & Griffiths, R. R. (2017).
Potential therapeutic effects of psilocybin.
Neurotherapeutics, 14, 734–740. https://doi.
org/10.1007/s13311-017-0542-y
Johnson, M. W., Richards, W. A., & Griffiths, R.
R. (2008). Human hallucinogen research:
Guidelines for safety. Journal of Psychopharmacology, 22, 603–620. https://doi.org/10.
1177/0269881108093587
Kast, E. (1966). LSD and the dying patient. The
Chicago Medical School Quarterly, 26, 80–87.
Kearney, M. (2000). A place of healing: Working with
suffering in living and dying. Oxford University Press.
Kiken, L. G., Garland, E. L., Bluth, K., Palsson,
O. S., & Gaylord, S. A. (2015). From a state
to a trait: Trajectories of state mindfulness in
meditation during intervention predict changes
in trait mindfulness. Personality and Individual
Differences, 81, 41–46.
King, D. B., & DeCicco, T. L. (2009). A viable model
and self-report measure of spiritual intelligence.
International
Journal
of
Transpersonal
Studies, 28, 68–85. https://doi.org/10.24972/
ijts.2009.28.1.68
Krebs, T. S., & Johansen, P. Ø. (2013). Over 30
million psychedelic users in the United States.
F1000Research, 2, 1–5. https://doi.org/10.12688/
f1000research.2-98.v1
Krau, S. D. (2016). The difference between palliative
care and end of life care: More than semantics.
Nursing Clinics of North America, 51(3), ix–x.
Kurland, A. A. (1985). LSD in the supportive care
of the terminally ill cancer patient. Journal of
Psychoactive Drugs, 17, 279–290. https://doi.or
g/10.1080/02791072.1985.10524332
Leary, T., Litwin, G. H., & Metzner, R. (1963).
Reactions to psilocybin administered in a
supportive environment. Journal of Nervous
and Mental Disease, 137, 561–573. https://doi.
org/10.1097/00005053-196312000-00007
Leary, T., Metzner, R., & Alpert, R. (with Pinchbeck,
D.). (2007). The psychedelic experience: A

manual based on the Tibetan book of the dead.
Citadel Press.
LeMay, K., & Wilson, K. G. (2008). Treatment of
existential distress in life threatening illness: A
review of manualized interventions. Clinical
Psychology Review, 28, 472–493.
Levenson, M. R., Aldwin, C. M., & Cupertino, A.
P. (2001). Transcending the self: Towards a
liberative model of adult development. In A. L.
Neri (Ed.), Maturidade & velhice: Um enfoque
multidisciplinar (pp. 99–116). Papirus.
Levenson, M. R., Jennings, P. A., Aldwin, C. M., &
Shiraishi, R. W. (2005). Self-transcendence: Concep
tualization and measurement. International Journal
of Aging and Human Development, 60, 127–143.
https://doi.org/10.2190/XRXM-FYRA-7U0X-GRC0
Lifton, R. J. (1976). The life of the self: Toward a new
psychology. Simon and Schuster.
Ludwig, A. M. (1972). Altered states of consciousness. In C. T. Tart. (Ed.), Altered states of
consciousness (pp. 11–24). Anchor Books.
MacDonald, D. A., Friedman, H. L., Brewczynski,
J., Holland, D., Salagame, K. K. K., Mohan,
K. K., Gubrij, Z.O., & Cheong, H. W. (2015).
Spirituality as a scientific construct: Testing its
universality across cultures and languages. PLOS
One, 10, e0117701. https://doi.org/10.1371/
journal.pone.0117701
MacLean, K. A., Johnson, M. W., & Griffiths, R.
R. (2011). Mystical experiences occasioned by
the hallucinogen psilocybin lead to increases
in the personality domain of openness. Journal
of Psychopharmacology, 25, 1453–1461. https://
doi.org/10.1177/0269881111420188
Malone, T. C., Mennenga, S. E., Guss, J., Podrebarac,
S. K., Owens, L. T., Bossis, A. P., Belser, A.
B., Agin-Liebes, G., Bogenschutz, M. P., &
Ross, S. (2018). Individual experiences in four
cancer patients following psilocybin-assisted
psychotherapy. Frontiers in Pharmacology, 9,
256. https://doi:10.3389/fphar.2018.00256
Maltoni, M., Scarpi, E., Rosati, M., Derni, S.,
Fabbri, L., Martini, F., Amadori, D., & Nanni,
O. (2012). Palliative sedation in end-of-life care
and survival: A systematic review. Journal of
Clinical Oncology, 30, 1378–1383. https://doi.
org/10.1200/JCO.2011.37.3795

Psychedelic-Assisted Self-Transcendence at End-of-Life

International Journal of Transpersonal Studies

49

Marcia, J. E. (2010). Life transitions and stress in the
context of psychosocial development. In T. W.
Miller (Ed.), Handbook of stressful transitions
across the lifespan (pp. 19–34). Springer. https://
doi.org/10.1007/978-1-4419-0748-6_2
Maslow, A. H. (1971). The farther reaches of human
nature. Viking Press.
Masters, R. E. L., & Houston, J. (1966). The varieties
of psychedelic experience. Holt, Rinehart and
Winston.
McClain, C. S., Rosenfeld, B., & Breitbart, W.
(2003). Effect of spiritual well-being on end-oflife despair in terminally-ill cancer patients. The
Lancet, 361, 1603–1607.
Mithoefer, M. (2015). A manual for MDMA-assisted
psychotherapy in the treatment of posttraumatic
stress disorder. Retrieved from https://maps.
org/research-archive/mdma/MDMA-AssistedPsychotherapy-Treatment-Manual-Version719Aug15-FINAL.pdf
Meier, C. A. (1967). Ancient incubation and modern
psychotherapy. Northwestern University Press.
Merlin, M. D. (2003). Archaeological evidence for
the tradition of psychoactive plant use in the old
world. Economic Botany, 57, 295–323.
Montagne, M. (1996) The pharmakon phenomenon:
Cultural conceptions of drugs and drug use. In P.
Davis (Ed.) Contested ground: Public purpose and
private interest in the regulation of prescription
drugs (pp. 11–25). Oxford University Press.
Moss, E. L., & Dobson, K. S. (2006). Psychology,
spirituality, and end-of-life care: An ethical
integration? Canadian Psychology 47, 284–299.
Nelson, B., & Sass, L. A. (2008). The phenomenology
of the psychotic break and Huxley’s trip: Substance
use and the onset of psychosis. Psychopathology,
41, 346–355. https://doi.org/10.1159/000152376
Newberg, A. B., & d’Aquili, E. G. (2000). The neuropsychology of religious and spiritual experience.
Journal of Consciousness Studies, 7, 251–266.
Nichols, D. E. (2016). Psychedelics. Pharmacological
Reviews, 68, 264–355. https://doi.org/10.1124/
pr.115.011478
Nour, M. M., & Carhart-Harris, R. L. (2017).
Psychedelics and the science of self-experience.
British Journal of Psychiatry, 210, 177–179.
https://doi.org/10.1192/bjp.bp.116.194738

50

International Journal of Transpersonal Studies

Novak, S. J. (1997). LSD before Leary: Sidney
Cohen’s critique of 1950s psychedelic drug
research. Isis, 88, 87–110.
Nutt, D. J., King, L. A., & Phillips, L. D. (2010).
Drug harms in the UK: A multicriteria decision
analysis. The Lancet, 376, 1558–1565. https://
doi.org/10.1016/S0140-6736(10)61462-6
Nutt, D., King, L. A., Saulsbury, W., & Blakemore,
C. (2007). Development of a rational scale to
assess the harm of drugs of potential misuse. The
Lancet, 369, 1047–1053. https://doi.org/10.1016/
S0140-6736(07)60464-4
Pahnke, W. N. (1967). The contribution of the
psychology of religion to the therapeutic use of
the psychedelic substances. In H. A. Abramson
(Ed.), The use of LSD in psychotherapy and
alcoholism (pp. 629–649). Bobbs-Merrill.
Pahnke, W. N. (1969). The psychedelic mystical
experience in the human encounter with death.
Harvard Theological Review, 62, 1–21. https://
doi.org/10.1017/S0017816000027577
Pahnke, W. N., & Richards, W. A. (1966). Implications
of LSD and experimental mysticism. Journal of
Religion and Health, 5, 175–208. https://doi.
org/10.1007/BF01532646
Passie, T. (2007). Contemporary psychedelic
therapy: An overview. In M. J. Winkelman
& T. B. Roberts (Eds.), Psychedelic medicine:
New evidence for hallucinogenic substances as
treatments (pp. 45–68). Praeger.
Passie, T., Halpern, J. H., Stichtenoth, D. O.,
Emrich, H. M., & Hintzen, A. (2008). The
pharmacology of lysergic acid diethylamide:
a review. CNS Neuroscience & Therapeutics,
14, 295–314. https://doi.org/10.1111/j.17555949.2008.00059.x
Passie, T., Seifert, J., Schneider, U., & Emrich, H.
M. (2002). The pharmacology of psilocybin.
Addiction Biology, 7, 357–364. https://doi.
org/10.1080/1355621021000005937
Peterson, C., & Seligman, M. E. (2004). Character
strengths and virtues: A handbook and classification. American Psychological Association.
Phelps, J. (2017). Developing guidelines and competencies for the training of psychedelic therapists.
Journal of Humanistic Psychology, 57, 450–487.
https://doi.org/10.1177/0022167817711304
St. Arnaud

Reed, P. G. (1991). Toward a theory of selftranscendence: Deductive reformulation using
developmental theories. Advances in Nursing
Science, 13, 64–77. https://doi.org/10.1097/00
012272-199106000-00008
Reed, P. G. (2009). Demystifying self-transcendence
for mental health nursing practice and research.
Archives of Psychiatric Nursing, 23, 397–400.
https://doi.org/10.1016/j.apnu.2009.06.006
Richards, W. A. (2009). The rebirth of research
with entheogens: Lessons from the past
and hypotheses for the future. Journal of
Transpersonal Psychology, 41, 139–150.
Richards, W. A. (2016). Sacred knowledge:
Psychedelics
and
religious
experiences.
Columbia University Press.
Richards, W. A., Rhead, J. C., DiLeo, F. B., Yensen,
R., & Kurland, A. A. (1977). The peak experience
variable in DPT-assisted psychotherapy with
cancer patients. Journal of Psychedelic Drugs,
9, 1–10. https://doi.org/10.1080/02791072.1977.
10472020
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T.,
Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi,
K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L.
(2016). Rapid and sustained symptom reduction
following psilocybin treatment for anxiety and
depression in patients with life-threatening
cancer: A randomized controlled trial. Journal
of Psychopharmacology, 30, 1165–1180. https://
doi.org/10.1177/0269881116675512
Saunders, C. (1988). Spiritual pain. Journal of
Palliative Care, 4, 29–32.
Sessa, B. (2017). The psychedelic renaissance:
Reassessing the role of psychedelic drugs in 21st
century psychiatry and society. Muswell Hill Press.
Shelton, R. C., & Hendricks, P. S. (2016). Psilocybin
and palliative end-of-life care. Journal of
Psychopharmacology, 30, 1207–1208. https://
doi.org/10.1177/0269881116675764
Sinnott, J. (2000). Cognitive aspects of unitative
states: Spiritual self-realization, intimacy, and
knowing the unknowable. In M. E. Miller & A. N.
West (Eds.), Spirituality, ethics, and relationships
in adulthood (pp. 177–198). Psychosocial Press.
Shafranske, E. P., & Sperry, L. (2005). Addressing
the spiritual dimension in psychotherapy:

Introduction and overview. In L. Sperry
& E. Shafranske (Eds.), Spiritually oriented
psychotherapy (pp. 11–29). Washington, DC:
American Psychological Association. https://
doi.org/10.1037/10886-001
St. Arnaud, K. O., & Cormier, D. C. (2017). Psychosis
or spiritual emergency: The potential of
developmental psychopathology for differential
diagnosis. International Journal of Transpersonal
Studies, 36, 44–59. https://doi.org/10.24972/
ijts.2017.36.2.44
Stein, M. (2004). Spiritual and religious aspects
of modern analysis. In J. Cambray & L. Carter
(Eds.), Analytical psychology: Contemporary
perspectives in Jungian analysis (pp. 204–222).
Brunner-Routledge.
Strang, P., Strang, S., Hultborn, R., & Arnér, S. (2004).
Existential pain—an entity, a provocation,
or a challenge? Journal of Pain and Symptom
Management, 27, 241–250.
Strassman, R. J. (1984). Adverse reactions to
psychedelic drugs. A review of the literature.
Journal of Nervous and Mental Disease, 172,
577–595.
https://doi.org/10.1097/00005053198410000-00001
Streib, H., & Hood, R. W. (2013). Modeling the
religious field: Religion, spirituality, mysticism
and related world views. Implicit Religion, 16,
137–155.
https://doi.org/10.1558/imre.v16i2.1
33
Studerus, E., Kometer, M., Hasler, F., & Vollenweider,
F. X. (2011). Acute, subacute and long-term
subjective effects of psilocybin in healthy humans:
A pooled analysis of experimental studies. Journal
of Psychopharmacology, 25, 1434–1452. https://
doi.org/10.1177/0269881110382466
Sundararjan, L. (2002). Religious awe: Potential
contributions of negative theology to
psychology, "positive" or otherwise. Journal of
Theoretical and Philosophical Psychology, 22,
174–197. https://doi.org/10.1037/h0091221
Sutich, A. J. (1973). Transpersonal therapy. Journal of
Transpersonal Psychology, 5, 1–6.
Swanson, L. R. (2018). Unifying theories of
psychedelic drug effects. Frontiers in
Pharmacology, 9, 172. https://doi.org/10.3389/
fphar.2018.00172

Psychedelic-Assisted Self-Transcendence at End-of-Life

International Journal of Transpersonal Studies

51

Swift, T. C., Belser, A. B., Agin-Liebes, G., Devenot,
N., Terrana, S., Friedman, H. L., Guss, J.,
Bossis, A. P., & Ross, S. (2017). Cancer at the
dinner table: Experiences of psilocybin-assisted
psychotherapy for the treatment of cancer-related
distress. Journal of Humanistic Psychology, 57,
488–519. doi.org/10.1177/0022167817715966
Tart, C. T. (1975). States of consciousness. Dutton.
Tillich, P. (1952). The courage to be. Yale University
Press.
Tomer, A., & Eliason, G. T. (2008). Existentialism and
death attitudes. In A. Tomer, G. T. Eliason, & P.
T. P. Wong (Eds.), Existential and spiritual issues
in death attitudes (pp. 7–37). Lawrence Erlbaum
Associates.
Tornstam, L. (1989). Gero-transcendence: A
reformulation of the disengagement theory.
Aging Clinical and Experimental Research, 1,
55–63. https://doi.org/10.1007/BF03323876
Vardy, M. M., & Kay, S. R. (1983). LSD psychosis
or LSD-induced schizophrenia?: A multimethod
inquiry. Archives of General Psychiatry, 40,
877–883.
https://doi.org/10.1001/archpsyc.19
83.01790070067008
Weenolsen, P. (1988). Transcendence of loss over
the life span. Hemisphere.
Weil, A. (1986). The natural mind: A new way of
looking at drugs and the higher consciousness.
Houghton Mifflin.
Wilber, K. (2006). Integral spirituality. Integral Books.
World Health Organization. (2019). WHO definition of palliative care. Retrieved from http://www.
who.int/cancer/palliative/definition/en/
Yaden, D. B., Haidt, J., Hood Jr, R. W., Vago, D.
R., & Newberg, A. B. (2017). The varieties of
self-transcendent experience. Review of General
Psychology, 21, 143–160. https://doi.org/10.1037/
gpr0000102
Yalom, I. (2008). Staring at the sun: Overcoming the
terror of death. Jossey-Bass.

About the Author
Kevin O. St. Arnaud, PhD, is a licensed psychologist
and assistant professor of psychology at Concordia
University of Edmonton. His research primarily
concerns the role for psychedelics in adult
developmental psychology, and the establishment
of frameworks for conceptualizing positive
psychoactive drug use. He previously worked as
a clinician in psychosocial oncology and palliative
care at the Cross Cancer Institute.
About the Journal
The International Journal of Transpersonal Studies
is a is a peer-reviewed academic journal in print
since 1981. It is sponsored by the California
Institute of Integral Studies, published by
Floraglades Foundation, and serves as the official
publication of the International Transpersonal
Association. The journal is available online at www.
transpersonalstudies.org, and in print through www.
lulu.com (search for IJTS).

Acknowledgments
The author would like to thank Dr. Ben Zalkind, the
editors at IJTS, and the reviewers of this manuscript
for their helpful suggestions and editorial assistance.

52

International Journal of Transpersonal Studies

St. Arnaud

